On Friday, the FDA approved Bayer’s dual neurokinin (NK) targeted therapy elinzanetant, which will now be marketed in the U.S ...

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...

Ipsen unveiled a new educational initiative dedicated to supporting teenagers and young adults in the transition from their ...

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...

As the industry's competition in the rare kidney disease IgA nephropathy (IgAN) heats up in the U.S., Roche’s Chugai Phar | Last year, Japan's Renalys picked up certain Asian rights to the IgAN ...

Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies.

Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...

With another quarter of growth in the books, Swiss CDMO Lonza is continuing to regain its forward momentum as it seeks to ...

To reach the target audience of geographic atrophy (GA) treatment Izervay, Astellas Pharma has turned to the “internet’s ...

In a new white paper, Havas Lynx lays out ways in which pharma marketers can—and should, according to the health comms agency ...

For the first nine months of 2025, Roche’s overall sales grew 7% at constant currencies to 45.9 billion Swiss francs (nearly ...

Dermatology specialist Galderma has hopped on the U.S. manufacturing bandwagon, revealing a commitment to spend more than ...